Cargando…

The efficacy and safety of bevacizumab in addition to platinum-based chemotherapy for the first-line treatment of patients with advanced nonsquamous non-small-cell lung cancer: Final results of AVALANCHE, an observational cohort study

The previous results of former clinical studies confirmed that first-line bevacizumab (BEV) in combination with chemotherapy improves clinical outcomes in patients with advanced non-squamous non-small cell lung cancer. The AVALANCHE study (ClinicalTrials.gov Identifier NCT03170284) was undertaken to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tolnay, Edina, Ghimessy, Áron Kristóf, Juhász, Erzsébet, Sztancsik, Zsuzsanna, Losonczy, György, Dombi, Péter, Vennes, Zsuzsanna, Helf, László, Csada, Edit, Sárosi, Veronika
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341671/ https://www.ncbi.nlm.nih.gov/pubmed/30675234 http://dx.doi.org/10.3892/ol.2018.9766

Ejemplares similares

Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First‐Line Nonsquamous Non‐Small Cell Lung Cancer
por: von Pawel, Joachim, et al.
Publicado: (2018)

KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy
por: Ghimessy, Áron Kristof, et al.
Publicado: (2019)

Efficacy of paclitaxel‐carboplatin with bevacizumab as a late‐line therapy for patients with advanced nonsquamous non‐small cell lung cancer: A platinum rechallenge
por: Sugisaka, Jun, et al.
Publicado: (2023)

Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience
por: Greillier, Laurent, et al.
Publicado: (2016)

Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non–small cell lung cancer (WJOG 5910L)
por: Takeda, Masayuki, et al.
Publicado: (2012)

Bevacizumab for the treatment of nonsquamous non-small-cell lung cancer in Portugal: a retrospective, multicenter study
por: Estevinho, Fernanda, et al.
Publicado: (2012)

Phase II study of carboplatin, pemetrexed, and bevacizumab in advanced nonsquamous non–small‐cell lung cancer
por: Laslett, Nicole F., et al.
Publicado: (2018)

Combination of Palliative Thoracic Radiotherapy With Bevacizumab for Stage IV Nonsquamous NSCLC: Is There Any Impact of Time Interval on Survival?
por: Xiu, Weigang, et al.
Publicado: (2022)

Rheumatoid arthritis and smoking: putting the pieces together
por: Baka, Zsuzsanna, et al.
Publicado: (2009)

Pembrolizumab plus pemetrexed‐platinum for metastatic nonsquamous non–small‐cell lung cancer: KEYNOTE‐189 Japan Study
por: Horinouchi, Hidehito, et al.
Publicado: (2021)

The Safety and Effectiveness of Bevacizumab in the Treatment of Nonsquamous Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Zhou, Yue, et al.
Publicado: (2021)

Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study
por: Tsutani, Yasuhiro, et al.
Publicado: (2018)

Protein Phosphatase 4 Is Required for Centrobin Function in DNA Damage Repair
por: Réthi-Nagy, Zsuzsánna, et al.
Publicado: (2023)

Better efficacy of intrapleural infusion of bevacizumab with pemetrexed for malignant pleural effusion mediated from nonsquamous non-small cell lung cancer
por: Song, Xinyu, et al.
Publicado: (2018)

Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study
por: Zhang, Jie, et al.
Publicado: (2021)

Phase 3 Trial of BI 695502 Plus Chemotherapy Versus Bevacizumab Reference Product Plus Chemotherapy in Patients With Advanced Nonsquamous NSCLC
por: Kim, Edward S., et al.
Publicado: (2021)

Ultrafast Gene Fusion Assessment for Nonsquamous NSCLC
por: Hofman, Véronique, et al.
Publicado: (2022)

Impact of Results of TTF-1 Immunostaining on Efficacy of Platinum-Doublet Chemotherapy in Japanese Patients with Nonsquamous Non-Small-Cell Lung Cancer
por: Nakao, Akira, et al.
Publicado: (2022)

Comparing the cost-effectiveness of sintilimab + pemetrexed plus platinum and pemetrexed plus platinum alone as a first-line therapy for Chinese patients with nonsquamous non-small cell lung cancer
por: Shi, Yafei, et al.
Publicado: (2023)

The Role of Combination Maintenance with Pemetrexed and Bevacizumab for Advanced Stage Nonsquamous Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Shan, Feiyu, et al.
Publicado: (2018)

An Open‐Label Phase II Trial of Bevacizumab plus Docetaxel and Gemcitabine in Advanced, Previously Untreated Nonsquamous Non‐Small Cell Lung Cancer
por: Patil, Pradnya Dinkar, et al.
Publicado: (2019)

Impact of prolonged and early bevacizumab treatment on the overall survival of EGFR‐mutant and EGFR‐wild type nonsquamous non‐small cell lung cancer
por: Huang, Yu‐Chen, et al.
Publicado: (2018)

Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501)
por: Watanabe, Satoshi, et al.
Publicado: (2022)

Ultrasensitive probing of plasmonic hot electron occupancies
por: Budai, Judit, et al.
Publicado: (2022)

Pemetrexed and Platinum Plus Pembrolizumab in Patients With Metastatic Nonsquamous NSCLC by Tumor Burden at Baseline: A Post Hoc Efficacy Analysis of KEYNOTE-189
por: Gadgeel, Shirish, et al.
Publicado: (2022)

Using the neutrophil‐to‐lymphocyte ratio to predict the outcome of individuals with nonsquamous non‐small cell lung cancer receiving pembrolizumab plus platinum and pemetrexed
por: Imai, Hisao, et al.
Publicado: (2023)

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer
por: Della Pepa, Chiara, et al.
Publicado: (2014)

Students in Danger: Binge Drinking Behaviour and Associated Factors in Hungary
por: Lukács, Anita, et al.
Publicado: (2021)

Single pemetrexed is noninferior to platinum-based pemetrexed doublet as first-line treatment on elderly Chinese patients with advanced nonsquamous nonsmall cell lung cancer
por: Pu, Xiaolin, et al.
Publicado: (2017)

Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study
por: Garassino, Marina C., et al.
Publicado: (2023)

Predictive Impact of Diffuse Positivity for TTF-1 Expression in Patients Treated With Platinum-Doublet Chemotherapy Plus Immune Checkpoint Inhibitors for Advanced Nonsquamous NSCLC
por: Terashima, Yuto, et al.
Publicado: (2023)

Feasibility study of first-line chemotherapy using Pemetrexed and Bevacizumab for advanced or recurrent nonsquamous non-small cell lung cancer in elderly patients: TORG1015
por: Kozuki, Toshiyuki, et al.
Publicado: (2016)

Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non–Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak Trials
por: Langer, Corey J., et al.
Publicado: (2016)

Equivalent efficacy assessment of QL1101 and bevacizumab in nonsquamous non-small cell lung cancer patients: A two-year follow-up data update
por: Lu, Jun, et al.
Publicado: (2022)

Oligonucleotide Formulations Prepared by High-Speed Electrospinning: Maximizing Loading and Exploring Downstream Processability
por: Hirsch, Edit, et al.
Publicado: (2023)

A phase I study of the tyrosine kinase inhibitor anlotinib combined with platinum/pemetrexed-based chemotherapy in untreated nonsquamous non-small-cell lung cancer
por: Huang, Meijuan, et al.
Publicado: (2021)

Potential Role of VHL, PTEN, and BAP1 Mutations in Renal Tumors
por: Szegedi, Krisztián, et al.
Publicado: (2023)

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer [Corrigendum]
Publicado: (2014)

Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer
por: Pujade-Lauraine, Eric
Publicado: (2013)

Short-term radiofrequency exposure from new generation mobile phones reduces EEG alpha power with no effects on cognitive performance
por: Vecsei, Zsuzsanna, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_djf2flp0hfnsu6acqsu7k28ta5